Everything below concerns GHRH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-15. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
=== Asymmetric copper-catalyzed allylic substitution === Mechanistically, oxidative addition is the step that determines which enantiomer is formed. Chiral ligands on the metal center along with low temperatures are the general tactics employed to produce an enantiopure product. In particular, the careful pairing of ligand classes with the type of nucleophile has proven to be essential. With Grignard reagents, ferrocenyl thiolate, phosphorus, and NHC ligands are typically used. There have also been several methods developed using diorganozinc nucleophiles coupled with phosphorus, amine, peptide, and NHC ligands. The scope of organoaluminium nucleophiles is comparatively smaller, but there have been a couple examples using NHC ligands. There is a need for more studies to better understand the mechanism of stereoinduction to expand the known set of reactions to encompass a larger overall substrate scope and to potentially allow for enantioselectivity at room temperature.
==== Risk of an oil spill ==== The FSO Safer, a floating oil storage and offloading tanker moored off Yemen’s Red Sea coast and holding around 1.1 million barrels of oil, has become a major humanitarian concern for the country. Since 2015, the vessel has not received proper maintenance, and experts have warned that corrosion or technical failure could lead to a large spill. Modelling exercises suggest that a serious spill could force the closure of major Red Sea ports such as Hudaydah and Salif, with the port of Aden possibly also affected in the Gulf of Aden. Such a scenario would cause an interruption of food assistance and a dramatically acute fuel shortage, among other consequences, and worsen the already severe humanitarian challenges the country is facing.
=== Inhibitors === Increased serum [Ca2+]. Severe decreases in serum [Mg2+], which also produces symptoms of hypoparathyroidism (such as hypocalcemia). Calcitriol Increase in serum phosphate. Fibroblast growth factor-23 (FGF23) is produced in osteoblasts (from bone) in response to increases in serum phosphate (Pi). It binds to the fibroblast growth factor receptor of the parathyroid and suppresses PTH release. This may seem contradictory because PTH actually helps rid the blood of phosphates but it is also causes release of phosphate into the blood from bone resorption. FGF23 inhibits PTH and then takes its place helping inhibit re-absorption of phosphate in the kidney without the phosphate releasing effect on bones.
Sources: en.wikipedia.org
== Contraindications == Pentoxyverine is contraindicated in persons with bronchial asthma or other kinds of respiratory insufficiency (breathing difficulties), as well as angle-closure glaucoma. No data are available for the use of pentoxyverine during pregnancy, lactation, or children under two years of age, wherefore the drug must not be used under these circumstances. Antitussive drugs are not useful in patients with extensive phlegm production because they prevent coughing up the phlegm.
=== Non-medical use === Enobosarm and other SARMs are sold as designer drugs by black-market vendors on the Internet. These agents have increasingly become used by the general public as "gym supplements" such as pre-workout or lifestyle drugs, rather than as an aid to performance in athletic or bodybuilding competitions. In one survey, 2.7% of young male gym users in the Netherlands reported using SARMs. In addition, a 2018 analysis of a fatberg from a sewer in central London showed enobosarm to be the most abundant "pharmaceutical drug" detected, and was present at higher concentration than recreational drugs such as MDMA and cocaine. While this isolated result may not be representative of overall levels of use, for enobosarm to be detectable in sewer deposits reflects significant levels of enobosarm use in the area close to where the sample was collected. Doses of enobosarm sold online and used non-medically are often many times higher than those assessed in clinical trials. Aside from enobosarm, the other most commonly used SARMs include vosilasarm (RAD140; "testolone"), LGD-4033 (VK5211; "ligandrol"), and andarine (GTx-007; S-4). Many products sold online that are purported to be enobosarm either contain none or contain other unrelated substances, and doses are also frequently not as labeled. Social media has played an important role in facilitating the widespread non-medical use of SARMs.
=== Dual-flow === Dual-flow, also known as dual, countercurrent chromatography occurs when both phases are flowing in opposite directions inside the column. Instruments are available for dual-flow operation for both Hydrodynamic and hydrostatic CCC. Dual-flow countercurrent chromatography was first described by Yoichiro Ito in 1985 for foam CCC where gas-liquid separations were performed. Liquid–liquid separations soon followed. The countercurrent chromatography instrument must be modified so that both ends of the column have both inlet and outlet capabilities. This mode may accommodate continuous or sequential separations with the sample being introduced in the middle of the column or between two bobbins in a hydrodynamic instrument. A technique called intermittent countercurrent extraction (ICcE) is a quasi-continuous method where the flow of the phases is alternated "intermittently" between normal and reversed-phase elution so that the stationary phase also alternates.
Sources: en.wikipedia.org
Avenir Suisse, founded in 1999 by fifteen of the largest Swiss companies. It is supported by over 130 companies to date. DCAF, the Geneva Centre for the Democratic Control of Armed Forces, founded in 2000 to research security sector governance and reform. Gottlieb Duttweiler Institute (GDI), conceived by Migros-founder Gottlieb Duttweiler in 1946. Horasis, which hosts the annual Horasis Global Meeting Liberal Institute, founded in 1979.
Conflict Analysis Resources Center. Archived from the original on July 4, 2007. Colombian-based private research center that studies the conflict (In Spanish and English) "Colombian Army website". Archived from the original on September 27, 2007. Retrieved February 24, 2006. (In Spanish and English) "Colombian President's Office". Archived from the original on November 18, 2008. Retrieved February 24, 2006. (In Spanish and English) "Background Note: Colombia". U.S. Department of State. Retrieved February 11, 2006. "Different Views of Colombian Territory". Retrieved February 24, 2006. Maps of the conflict. "AUC Official Website". Retrieved February 24, 2006. (in Spanish) "FARC website". Archived from the original on July 5, 2008. Retrieved July 12, 2008. (in Spanish and English) – No longer available online (censored by U.S. government) "Civil War? The Language of Conflict in Colombia" (PDF). Ideas for Peace Foundation. Archived from the original (PDF) on September 10, 2009. Retrieved February 24, 2006. (PDF) Is the Colombia conflict a civil war? "The Peace Village San José Must Live". SOS San Jose. Archived from the original on January 12, 2006. Retrieved February 24, 2006. (in German and English) "Washington Office on Latin America". Retrieved February 24, 2006. "Who Shot My Brother?". National Film Board of Canada. Archived from the original on May 24, 2007. Retrieved May 27, 2018. "Why the End of the Cold War Doesn't Matter: the US War of Terror in Colombia". Bristol University Politics Department. Archived from the original on October 1, 2005.
=== Venom === Although these spiders are capable of hunting and killing some of the most venomous spiders in the world such as the redback spider, they are not dangerous to humans. According to researchers Greta Binford and Pamela Zobel-Thropp, the effects of P. phalangioides venom on humans and other mammals are negligible. In humans, the P. phalangioides bite simply results in a mild stinging sensation that has no long-term health consequences.
== Function == Nicotinamide phosphoribosyltransferase (iNAMPT) catalyzes the condensation of phosphoribosyl pyrophosphate with nicotinamide (NAM) to yield nicotinamide mononucleotide (NMN) and pyrophosphate (PPi). This is the first step in the biosynthesis of nicotinamide adenine dinucleotide (NAD+). This reaction allows a salvage pathway, in which NAM is recycled from enzymes that use NAD+ (sirtuins, PARPs, CD38) as these produce NAM as a waste product. Thus this reaction is a major source of NAD+ production in the body. De novo synthesis of NAD+ from tryptophan occurs only in the liver and kidney, overwhelmingly in the liver.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.